Dr. Peter Haberz is the Principal of LYZZ Capital. Bofore joining LYZZ Capital, Peter was the Senior Director of Business Development at MEI Pharma, a NASDAQ listed late-stage oncology drug development company where he shaped the corporate strategy and closed corporate alliances in excess of $1.5B. He joined MEI Pharma from The Scripps Research Institute where he served as Technology Development Officer and oversaw a portfolio of over 100 early-stage technologies resulting in licenses worth over $20M. Peter also held board observer positions at two Scripps spin-off companies, Synthorx and Epic Sciences.
Peter received a master’s degree in chemistry from the University of Graz, Austria, a doctorate in chemistry from the Max-Planck Institute for Biophysical Chemistry in Göttingen, Germany, and postdoctoral training from The Scripps Research Institute, La Jolla.
